{"id":"W2759277150","doi":"10.1186/s13045-017-0527-7","title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","year":2017,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":298,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Novartis Pharma; Genentech; AOP Orphan; CTI Biopharma; Incyte; Baxalta; Ariad Pharmaceuticals; Gilead Sciences; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Hazard ratio; Randomized controlled trial; International Prognostic Scoring System; Clinical endpoint; Anemia; Hematology; Placebo; Survival analysis; Proportional hazards model; Clinical trial; Subgroup analysis; Surgery; Confidence interval; Bone marrow; Myelodysplastic syndromes; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01027473,0.001461017,0.005188711,0.001245032,0.0001863338,0.00113307,0.0007394201,0.0008007174,0.001861192],"category_scores_gemma":[0.007005092,0.0005512846,0.01405232,0.001390881,0.0002726083,0.0006618819,0.0009368722,0.0007733499,0.0001643314],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005316878,"about_ca_system_score_gemma":0.0005433262,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001256139,"about_ca_topic_score_gemma":0.002682637,"domain_scores_codex":[0.9932885,0.003926977,0.0008600724,0.001024813,0.0006492737,0.000250397],"domain_scores_gemma":[0.9940263,0.00305162,0.001666381,0.0005855464,0.0004230124,0.0002470796],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.2459523,0.000253063,0.1659951,0.006755828,0.5485014,0.0002242024,0.0001575799,0.003706876,0.002552333,0.0001820272,0.002266159,0.02345305],"study_design_scores_gemma":[0.02489807,0.01910927,0.5107527,0.0007615088,0.4322116,0.0004510994,0.0002723973,0.005020105,0.001319949,0.0003717096,0.004655886,0.0001757287],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9101316,0.0736516,0.002989886,0.0001877415,0.0002487161,0.0007350253,0.01001909,0.00009698042,0.001939334],"genre_scores_gemma":[0.9874106,0.00427329,0.0009788951,0.0001911297,0.000228006,0.0006483243,0.005753489,0.00002248577,0.0004937432],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01027473,"threshold_uncertainty_score":0.05433857,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0497649413758295,"score_gpt":0.3819046456399105,"score_spread":0.332139704264081,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}